

# Jasvinder A Singh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10836556/publications.pdf>

Version: 2024-02-01

96  
papers

29,345  
citations

94269

37  
h-index

48187

88  
g-index

96  
all docs

96  
docs citations

96  
times ranked

43315  
citing authors

#	ARTICLE	IF	CITATIONS
1	Perioperative assessment of muscle inflammation susceptibility in patients with end-stage osteoarthritis. <i>Journal of Applied Physiology</i> , 2022, 132, 984-994.	1.2	8
2	Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 655-667.	5.5	43
3	Treatment Guidelines in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 679-689.	0.8	21
4	Flare Rate Thresholds for Patient Assessment of Disease Activity States in Gout. <i>Journal of Rheumatology</i> , 2021, 48, 293-298.	1.0	11
5	Pop a pill or give myself a shot? Patient perspectives of disease-modifying anti-rheumatic drug choice for rheumatoid arthritis. <i>Joint Bone Spine</i> , 2021, 88, 105053.	0.8	3
6	Traitement anti-TNF ou non anti-TNF dans la polyarthrite rhumatoïde active: facteurs déterminant le choix des patients. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021, 88, 49-55.	0.0	0
7	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 924-939.	1.5	466
8	2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1108-1123.	2.9	339
9	Prendre un comprimé ou me faire une injection? Point de vue des patients quant au choix des traitements de fond (DMARD) dans la polyarthrite rhumatoïde (PR). <i>Revue Du Rhumatisme (Edition) Tj ETQq1 1 00784314 rgBT /Ove</i>		
10	Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in a US Veterans Affairs Gout Cohort. <i>Journal of Rheumatology</i> , 2020, 47, 449-460.	1.0	11
11	Severity of Hypertension Mediates the Association of Hyperuricemia With Stroke in the REGARDS Case Cohort Study. <i>Hypertension</i> , 2020, 75, 246-256.	1.3	37
12	A Randomized Internet-Based Pilot Feasibility and Planning Study of Cherry Extract and Diet Modification in Gout. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 147-156.	0.5	9
13	Patient-Centered Outcomes and Key Study Procedure Finalization in the Pilot Feasibility Gout Randomized Trial. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 181-191.	0.5	2
14	Allopurinol adherence and its predictors in gout: a national cohort study in US veterans. <i>Lancet Rheumatology, The</i> , 2020, 2, e281-e291.	2.2	7
15	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis and Rheumatology</i> , 2020, 72, 879-895.	2.9	302
16	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis Care and Research</i> , 2020, 72, 744-760.	1.5	420
17	Important determinants of the patient choice between TNF- vs. non-TNF Biologic disease-modifying anti-rheumatic drugs (DMARDs) for active rheumatoid arthritis (RA). <i>Joint Bone Spine</i> , 2020, 87, 307-313.	0.8	4
18	Patient Perceptions of Gout Management Goals. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 129-133.	0.5	11

#	ARTICLE	IF	CITATIONS
19	Gout epidemiology and comorbidities. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, S11-S16.	1.6	157
20	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 245-266.	3.7	823
21	Gout is associated with an increased risk for incident heart failure among older adults: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort study. <i>Arthritis Research and Therapy</i> , 2020, 22, 86.	1.6	21
22	Filgotinib, a JAK1 Inhibitor, for Treatment-Resistant Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 309.	3.8	11
23	Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1592-1600.	0.5	72
24	Is there a role for cherries in the management of gout?. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2019, 11, 1759720X1984701.	1.2	11
25	Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy. <i>Drugs</i> , 2019, 79, 531-541.	4.9	36
26	Gout and sexual function: patient perspective of how gout affects personal relationships and intimacy. <i>BMC Rheumatology</i> , 2019, 3, 8.	0.6	8
27	Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?. <i>Drugs and Aging</i> , 2019, 36, 493-510.	1.3	16
28	Patient perspectives in gout: a review. <i>Current Opinion in Rheumatology</i> , 2019, 31, 159-166.	2.0	7
29	Race, Discharge Disposition, and Readmissions After Elective Hip Replacement: Analysis of a Large Regional Dataset. <i>Health Equity</i> , 2019, 3, 628-636.	0.8	16
30	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 31-58.	0.3	12
31	Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: reality or dream?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 153-154.	0.5	0
32	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	2.9	312
33	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	1.5	264
34	The State of US Health, 1990-2016. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1444.	3.8	1,042
35	Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout. <i>Arthritis Care and Research</i> , 2018, 70, 659-671.	1.5	19
36	Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements. <i>Journal of Rheumatology</i> , 2018, 45, 419-424.	1.0	15

#	ARTICLE	IF	CITATIONS
37	Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 293-301.	1.6	32
38	EULAR gout treatment guidelines by Richette et al.: uric acid and neurocognition. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e20-e20.	0.5	3
39	Medication adherence among patients with gout: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 689-702.	1.6	108
40	Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 235-252.	1.2	14
41	Expert opinion on emerging urate-lowering therapies. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 201-209.	1.0	22
42	Goals of gout treatment: a patient perspective. <i>Clinical Rheumatology</i> , 2018, 37, 2557-2566.	1.0	8
43	Recommendations for the management of rheumatoid arthritis in the Eastern Mediterranean region: an adoption of the 2015 American College of Rheumatology guidelines. <i>Clinical Rheumatology</i> , 2018, 37, 2947-2959.	1.0	13
44	Gout Self-Management in African American Veterans: A Qualitative Exploration of Challenges and Solutions From Patients' Perspectives. <i>Arthritis Care and Research</i> , 2017, 69, 1724-1732.	1.5	15
45	Chasing crystals out of the body: will treat to serum urate target for gout help us get there?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 629-631.	0.5	5
46	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017, 2017, CD012591.	1.5	44
47	Safety of Biologic and Nonbiologic Disease-modifying Antirheumatic Drug Therapy in Veterans with Rheumatoid Arthritis and Hepatitis C Virus Infection. <i>Journal of Rheumatology</i> , 2017, 44, 565-570.	1.0	9
48	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2017, 5, CD012657.	1.5	47
49	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. <i>New England Journal of Medicine</i> , 2017, 377, 13-27.	13.9	5,014
50	Patient Endorsement of the Outcome Measures in Rheumatology (OMERACT) Total Joint Replacement (TJR) clinical trial draft core domain set. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 111.	0.8	23
51	Racial differences in health-related quality of life and functional ability in patients with gout. <i>Rheumatology</i> , 2017, 56, 103-112.	0.9	14
52	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 699-708.	1.6	19
53	Adaptation of the 2015 American College of Rheumatology treatment guideline for rheumatoid arthritis for the Eastern Mediterranean Region: an exemplar of the GRADE Adoption. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 183.	1.0	25
54	Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1870-1882.	0.5	98

#	ARTICLE	IF	CITATIONS
55	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , 2016, 68, 667-672.	1.5	48
56	Gout: will the "King of Diseases" be the first rheumatic disease to be cured?. <i>BMC Medicine</i> , 2016, 14, 180.	2.3	20
57	Time Trends, Predictors, and Outcome of Emergency Department Use for Gout: A Nationwide US Study. <i>Journal of Rheumatology</i> , 2016, 43, 1581-1588.	1.0	21
58	Development of the American College of Rheumatology's Rheumatoid Arthritis Electronic Clinical Quality Measures. <i>Arthritis Care and Research</i> , 2016, 68, 1579-1590.	1.5	43
59	Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies. <i>Current Rheumatology Reports</i> , 2016, 18, 61.	2.1	32
60	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1-25.	1.5	890
61	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1-26.	2.9	1,880
62	Allopurinol and the risk of stroke in older adults receiving medicare. <i>BMC Neurology</i> , 2016, 16, 164.	0.8	26
63	Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). <i>The Cochrane Library</i> , 2016, 2016, CD012437.	1.5	27
64	Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis. <i>BMJ Open</i> , 2016, 6, e012026.	0.8	5
65	Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. <i>The Cochrane Library</i> , 2016, 2016, CD012183.	1.5	51
66	Gout-related inpatient utilization: a study of predictors of outcomes and time trends. <i>Arthritis Research and Therapy</i> , 2016, 18, 57.	1.6	12
67	A cross-sectional internet-based patient survey of the management strategies for gout. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 90.	3.7	18
68	Total joint replacement surgery for knee osteoarthritis and other non-traumatic diseases: a network meta-analysis. <i>The Cochrane Library</i> , 2015, , .	1.5	4
69	Subcutaneous or intramuscular methotrexate for rheumatoid arthritis. <i>The Cochrane Library</i> , 2015, , .	1.5	0
70	A Real-World Study of Switching From Allopurinol to Febuxostat in a Health Plan Database. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 411-418.	0.5	11
71	Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2015, 17, 136.	1.6	13
72	Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. <i>Arthritis Research and Therapy</i> , 2015, 17, 120.	1.6	52

#	ARTICLE	IF	CITATIONS
73	Investigational drugs for hyperuricemia. Expert Opinion on Investigational Drugs, 2015, 24, 1013-1030.	1.9	44
74	Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet, The, 2015, 386, 258-265.	6.3	487
75	Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists. PLoS ONE, 2015, 10, e0135805.	1.1	8
76	Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: A 13-year study of time trends. BMC Musculoskeletal Disorders, 2014, 15, 441.	0.8	52
77	The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout. Arthritis Research and Therapy, 2014, 16, R132.	1.6	57
78	Remembering the forgotten non-communicable diseases. BMC Medicine, 2014, 12, 200.	2.3	82
79	Updated Method Guidelines for Cochrane Musculoskeletal Group Systematic Reviews and Metaanalyses. Journal of Rheumatology, 2014, 41, 194-205.	1.0	124
80	Impaired response or insufficient dosage? Examining the potential causes of inadequate response to allopurinol in the treatment of gout. Seminars in Arthritis and Rheumatism, 2014, 44, 170-174.	1.6	43
81	Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis Research and Therapy, 2014, 16, R82.	1.6	60
82	Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 766-781.	6.3	9,122
83	The State of US Health, 1990-2010. JAMA - Journal of the American Medical Association, 2013, 310, 591.	3.8	2,070
84	Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy, 2013, 5, 265-299.	1.0	51
85	Is HLAB genotyping the future of gout pharmacogenomics?. Nature Reviews Rheumatology, 2013, 9, 200-202.	3.5	0
86	Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate. Cmaj, 2013, 185, 793-795.	0.9	3
87	Folic Acid Supplementation for Rheumatoid Arthritis Patients on Methotrexate: The Good Gets Better. , 2013, , ED000063.		7
88	Emerging therapies for gout. Expert Opinion on Emerging Drugs, 2012, 17, 511-518.	1.0	7
89	2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care and Research, 2012, 64, 1447-1461.	1.5	598
90	2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care and Research, 2012, 64, 1431-1446.	1.5	1,268

#	ARTICLE	IF	CITATIONS
91	2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 625-639.	1.5	1,413
92	Risk factors for gout and prevention: a systematic review of the literature. Current Opinion in Rheumatology, 2011, 23, 192-202.	2.0	202
93	Tocilizumab for rheumatoid arthritis. , 2010, , CD008331.		51
94	Golimumab for rheumatoid arthritis. The Cochrane Library, 2010, 2010, CD008341.	1.5	44
95	Biologics for rheumatoid arthritis: an overview of Cochrane reviews. , 2009, , CD007848.		174
96	Quality of care for gout in the US needs improvement. Arthritis and Rheumatism, 2007, 57, 822-829.	6.7	176